BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Core Insights - BriaCell Therapeutics Corp. has released new imaging data demonstrating the resolution of metastatic breast cancer lesions in patients with various organ involvements, highlighting the effectiveness of their immunotherapy treatment [1][6]. Patient Outcomes - Patient 11-018, a 66-year-old woman with ER+/PR+/HER2+ metastatic breast cancer, achieved 27 months of survival post-enrollment after 35 cycles of Bria-IMT treatment, showing complete resolution of temporal lobe metastasis and significant improvement in orbital lesions [2][4]. - Patient 15-005, a 44-year-old woman with ER+/PR+/HER2- metastatic breast cancer, remains in stable condition 27 months after treatment, having completed 6 cycles of therapy [9]. - Patient 15-006, a 64-year-old woman with ER+/PR-/HER2- metastatic breast cancer, has survived 25 months post-enrollment after receiving 4 cycles of Bria-IMT treatment [13]. Mechanism of Action - The CD8 ImmunoPET imaging confirms that BriaCell's treatment activates CD8+ cytotoxic T cells, which infiltrate tumors, potentially enhancing long-term patient survival even after treatment cessation [3]. Study Details - The Phase 2 study involved 54 heavily pre-treated metastatic breast cancer patients, with a median of six prior therapies, who received the Bria-IMT regimen alongside a checkpoint inhibitor. Notably, no treatment-related discontinuations have been reported [17].